|Year : 2021 | Volume
| Issue : 2 | Page : 89-91
NOTTO COVID-19 vaccine guidelines for transplant recipients
Vivek B Kute1, Sanjay K Agarwal2, Jai Prakash3, Sandeep Guleria4, Sunil Shroff5, Ashish Sharma6, Prem Varma7, Narayan Prasad8, Manisha Sahay9, Subhash Gupta10, S Sudhindran11, Kewal Krishan12, Vasanthi Ramesh13, Sunil Kumar14
1 Department of Nephrology, Institute of Kidney Diseases and Research Center and Dr. H L Trivedi Institute of Transplantation Sciences (IKDRC-ITS), Ahmedabad, Gujarat, India
2 Department of Nephrology, All India Institute of Medical Sciences, Delhi, India
3 Department of Nephrology, Banaras Hindu University, Varanasi, Uttar Pradesh, India
4 Department of Transplantation Surgery, Apollo Hospital, Delhi, India
5 Managing, Trustee, MOHAN Foundation, Chennai, Tamil Nadu, India
6 Department of Transplant Surgery, The Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
7 Department of Nephrology, Venkateshwar Hospital, Delhi, India
8 Department of Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
9 Department of Nephrology, Osmania Medical College, Hyderabad, Telangana, India
10 Department of Liver Transplant Surgery, Max Center of Liver and Biliary Sciences at Max Hospital, Saket, Delhi, India
11 Clinical Professor in Transplantation and Gastrointestinal Surgery, Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala, India
12 Department of Cardiovascular Surgery, Max super specialty Hospital, Saket, New Delhi, India
13 National Organ and Tissue Transplant Organization, New Delhi, India
14 Director General of Health Services, New Delhi, India
|Date of Submission||26-Feb-2021|
|Date of Acceptance||28-Feb-2021|
|Date of Web Publication||20-Apr-2021|
Dr. Vasanthi Ramesh
National Organ and Tissue Transplant Organization, 4th Floor, National Institute of Pathology, NIOP Building, Safdarjung Hospital Campus, New Delhi - 110 029
Source of Support: None, Conflict of Interest: None
In December 2019, novel coronavirus (SARS-CoV-2) infection started in Wuhan and resulted in a pandemic within a few weeks' time. Organ transplant recipients being at a risk for more severe COVID-19 if they get SARS CoV-2 viral infection, COVID-19 vaccine has a significant role in these patients. The vaccine is a safer way to help build protection and would either prevent COVID-19 infection or at least diminish the severity of the disease. It would also reduce the risk of the continuing transmission and enhance herd immunity. Immuno-compromised patients should not receive live vaccines as they can cause vaccine-related disease and hence the guidelines suggest that all transplant recipients should receive age-appropriate 'inactivated vaccine' as recommended for general population. Though trials have not been undertaken on transplant recipients, efficacy and safety of COVID-19 vaccine have been scientifically documented for few vaccines among the general population.
Keywords: COVID-19 vaccine, guidelines, NOTTO, transplant recipients
|How to cite this article:|
Kute VB, Agarwal SK, Prakash J, Guleria S, Shroff S, Sharma A, Varma P, Prasad N, Sahay M, Gupta S, Sudhindran S, Krishan K, Ramesh V, Kumar S. NOTTO COVID-19 vaccine guidelines for transplant recipients. Indian J Nephrol 2021;31:89-91
|How to cite this URL:|
Kute VB, Agarwal SK, Prakash J, Guleria S, Shroff S, Sharma A, Varma P, Prasad N, Sahay M, Gupta S, Sudhindran S, Krishan K, Ramesh V, Kumar S. NOTTO COVID-19 vaccine guidelines for transplant recipients. Indian J Nephrol [serial online] 2021 [cited 2022 Jan 19];31:89-91. Available from: https://www.indianjnephrol.org/text.asp?2021/31/2/89/313990
| Introduction|| |
With the use of COVID-19 appropriate behavior, in many countries, the incidence of COVID-19 is decreasing, though not with some degree in every country. With the development of safe vaccine against COVID-19, its global utilization is paramount. Transplant recipients being a high-risk group for COVID-19 infection, these vaccines are urgently required for these patients. The Centers for Disease Control and Prevention (CDC) suggests that COVID-19 vaccination will help in the prevention of COVID-19, is a safer way to help build protection, and will be an important tool to help in stopping the ongoing pandemic.
Advantages of getting a COVID-19 Vaccine:,,,,,
- Risk of acquiring COVID-19 infection goes down substantially.
- Risk of having severe COVID disease even if one acquires the infection is substantially reduced.
- The risk of continuing transmission to others will decrease
- Vaccine will help in faster development of herd immunity.
Rationale and General Principle for the Vaccination
SARS-Cov2 infection has significantly impacted transplant recipients, with high morbidity and mortality (5%-“35%%).,, Vaccination for these high-risk patients is a priority.
- Patients with immunosuppression may have reduced response to vaccination because of altered T lymphocyte functions. These patients may have lower antibody response compared to general population. Antibody response usually correlates with the degree of immunosuppression.
- In general, in immunocompromised patients, live vaccines can cause vaccine-related disease, therefore patients with organ transplant should not receive live vaccines.,, Kidney Disease: Improving Global Outcomes (KDIGO) and American Society of Transplantation- Infectious Disease Community of Practice (AST-IDCOP) guidelines suggest that all transplant recipients should receive age appropriate 'inactivated vaccine' as recommended for general population.,
- Efficacy and safety of COVID-19 vaccine has been scientifically documented only for few vaccines and many are still under clinical trial.,,, Initial trial of COVID-19 vaccine had included healthy volunteers, and patients with comorbidity but trials on transplant recipients have not been done till the publication of these guidelines.
- Participating recipients can have minor side effects as seen in many other vaccines like vaccine site pain, fever, fatigue, muscle and joint pain, and headache after administration of COVID-19 vaccine. These side effects do not mean vaccines are unsafe. Severe or long-lasting side effects are extremely rare. Also, COVID-19 vaccines are continuously being monitored for safety in post-marketing survey to detect rare adverse events.
- In cases of any adverse event, the transplant patient is required to report to health care providers for appropriate management. After the completion of COVID-19 schedule, routine antibody testing is not required to confirm seroconversion. If needed for research, antibody testing can be done after 14 days of the second dose.
- More studies are required to document energy, duration of immunity and requirement of booster dose in case no antibodies develop. [Table 1] shows details of few common regulatory bodies' approved COVID-19 vaccine.
COVID-19 vaccine guidelines
- We recommend that all transplant team members should support and encourage appropriate uptake of vaccine by counseling transplant recipients and addressing vaccine hesitancy.
- We recommend using virtual platforms for information related to COVID-19 vaccine for all transplant team members, who are a major source of information for the transplant recipient community.
- Based on other vaccine guidelines for solid organ transplant recipients,,,,, we suggest that transplant recipients and their household members should get vaccinated against any COVID-19 vaccine that is authorized or approved by their health regulators/agencies. Transplant recipients scheduled for transplantation, should be given vaccine two weeks prior to surgery or one to six months post-transplant., Even after vaccination, COVID-19 appropriate behaviors like wearing face mask, hand hygiene, cough etiquettes and social distancing should be continued by all recipients.
- Transplant recipients who have previous COVID-19 infection and or, have antibodies against COVID-19 are also required to be vaccinated. There is no need of testing for antibodies against coronavirus before giving COVID-19 vaccination. Transplant recipients should undergo the entire schedule of vaccination with only one type of vaccine and different COVID-19 vaccines should not be used in the same patient. In case, a transplant recipient misses the second dose of COVID-19 vaccine at scheduled time, then the second dose is to be given as early as possible. Revaccination is not required.
- Transplant patient with suspected or active SARS-Cov2 infection should NOT get vaccination. Vaccination should be deferred for 4-8 weeks after symptom resolution.
- Please see the details of COVID-19 vaccine operational guidelines updated as on 28 December 2020.,,
Disclaimer: COVID-19 pandemic is evolving in a dynamic manner, therefore, this COVID-19 vaccine Guideline is a live and dynamic document and will be updated as per the evolving situation. This is consensus Guidelines of National Organ and Tissue Transplant OrganisationIndian society of Organ Transplantation, Liver Transplant Society of India and Indian Society for Heart and Lung Transplantation as on January 19, 2021.
Note: This special article is being published simultaneously in the Indian Journal of Transplantation and the Indian Journal of Nephrology, as per the decision of Editor-In-Chiefs of both these journals.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Kute VB, Bhalla AK, Guleria S, Ray DS, Bahadur MM, Shingare A, et al
. Clinical Profile and outcome of COVID-19-19 in 250 kidney transplant recipients: A multicenter cohort study from India. Transplantation 2020. doi: 10.1097/TP.0000000000003593.
Raja MA, Mendoza MA, Villavicencio A, Anjan S, Reynolds JM, Kittipibul V, et al
. COVID-19-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature. Transplant Rev (Orlando) 2021;35:100588.
Craig-Schapiro R, Salinas T, Lubetzky M, Abel BT, Sultan S, Lee JR, et al
. COVID-19-19 outcomes in patients waitlisted for kidney transplantation and kidney transplant recipients. Am J Transplant 2020. doi: 10.1111/ajt.16351.
Guidelines for vaccination in kidney transplant recipients. Indian J Nephrol 2016;26(Suppl 1):S19-25.
Stucchi RSB, Lopes MH, Kumar D, Manuel O. Vaccine recommendations for solid-organ transplant recipients and donors. Transplantation 2018;102(Suppl 2):S72-80.
Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, et al
. Vaccination of haemopoietic stem cell transplant recipients: Guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 2019;19:e200-12.
Danziger-Isakov L, Kumar D; AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant 2019;33:e13563.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al
. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383:2603-15.
Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al
. Safety and immunogenicity of ChAdO×1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021;396:1979-93.
Ministry of health and family welfare guidelines for vaccination in COVID19 Available from: https://www.mohfw.gov.in
. [Last accessed on 2021 Jan 14].
|This article has been cited by|
||Update on Coronavirus 2019 Vaccine Guidelines for Transplant Recipients
| ||Vivek Kute, Hari Shankar Meshram, Ashish Sharma, Arpita Ray Chaudhury, S. Sudhindran, AllaGopala Krishna Gokhale, Milind Hote, Randeep Guleria, Devinder Singh Rana, Jai Prakash, Vasanthi Ramesh |
| ||Transplantation Proceedings. 2021; |
|[Pubmed] | [DOI]|
||Clinical Profiles and Outcomes of COVID-19 in Kidney Transplant Recipients: Experience From a High-Volume Public Sector Transplant Center in India
| ||Vivek B. Kute, Hari Shankar Meshram, Himanshu V. Patel, Divyesh Engineer, Subho Banerjee, Vijay V. Navadiya, Dev D. Patel, Akash Gupta, Sanshriti Chauhan, Vineet V. Mishra |
| ||Experimental and Clinical Transplantation. 2021; 19(9): 899 |
|[Pubmed] | [DOI]|